<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age/><report-id>PHHY2013IT007183</report-id><gender>female</gender><reactions><reaction>Osteonecrosis of jaw</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>ZOMETA</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Metastases to bone</indication></indications><outcomes/><country>Italy</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149699_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152636</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2013IT007183</safetyreportid>
		<primarysourcecountry>IT</primarysourcecountry>
		<occurcountry>IT</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-24</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-24</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2013IT007183</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>189999</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>IT</reportercountry>
			<qualification code="3">Other Health Professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Breast cancer</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Osteonecrosis of jaw</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Osteonecrosis of jaw</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Osteonecrosis of jaw</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20100101</reactionstartdate>
				<reactionfirsttime>1</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ZOMETA</medicinalproduct>
				<obtaindrugcountry>IT</obtaindrugcountry>
				<drugauthorizationnumb>21-223</drugauthorizationnumb>
				<drugauthorizationcountry>IT</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>4</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>4 mg, monthly</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Metastases to bone</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2010-01-01</drugstartdate>
				<drugstartperiod>1</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2010-04-01</drugenddate>
				<drugtreatmentduration>91</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ZOLEDRONATE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis of jaw</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis of jaw</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2013IT007183 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from <Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">other health care professional </Semaphore><Semaphore x="2009300" class="Occupation" value="Health Care Professional" score="1.00" ID="C53287">via Health </Semaphore>Authority (HAs 189999) received on 24 Jan 2013. This report refers to an unknown age female patient. Medical history included <Semaphore x="2826913" class="MedDRA LLT" value="Breast cancer" score="1.00" ID="10006187"><Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore>cancer</Semaphore>. The patient received <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.74" ID="242959">Zometa </Semaphore>(zoledonic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore>) for the <Semaphore x="1617732" class="Procedure" value="Bone Metastases Treatment" score="1.00" ID="C70812">treatment of <Semaphore x="1619584" class="AnatomicStructure" value="Bone" score="1.00" ID="C12366">bone </Semaphore><Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastases </Semaphore></Semaphore>from 01 Jan 2010 at a dose of 4 mg monthly. <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">Treatment </Semaphore>medications included <Semaphore x="173389" class="Medicine" value="Augmentin" score="0.49" ID="239493">Augmentin </Semaphore>(<Semaphore x="108837" class="Medicine" value="Amoxicillin" score="0.49" ID="281312">amoxicillin </Semaphore>and <Semaphore x="372706" class="Medicine" value="Clavulanic Acid" score="0.49" ID="247109">clavulanic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>) and <Semaphore x="870076" class="Medicine" value="metroNIDAZOLE" score="0.49" ID="280143">metronidazole</Semaphore>. On 01 Jan 2013, the patient developed <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">osteonecrosis </Semaphore>of jaw.Treatment with <Semaphore x="1385161" class="Medicine" value="Zometa" score="0.74" ID="242959">Zometa </Semaphore>was stopped on 01 Apr 2010. The case was assessed as serious (medically significant). Causality was reported as suspected. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was considered <Semaphore x="1409602" class="Procedure" value="About What Time is it" score="1.00" ID="C110931">unchanged</Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>